Glucoproteína P e infección por el virus de la inmunodeficiencia humana-Reference-Cited by-同舟云学术

Glucoproteína P e infección por el virus de la inmunodeficiencia humana

Published:2008-03 Issue:3 Volume:26 Page:150-159
ISSN:0213-005X
Container-title:Enfermedades Infecciosas y Microbiología Clínica
language:es
Short-container-title:Enfermedades Infecciosas y Microbiología Clínica

Author:

Peralta Galo,Blanca Sánchez María,Echevarría Santiago,María Valdizán Elsa,Antonio Armijo Juan

Publisher

Elsevier BV

Subject

Microbiology (medical)

Reference107 articles.

1. Antiretroviral therapy in previously untreated adults infected with the human immunodeficiency virus type I: established and potential determinants of virological outcome;Lowe;Neth J Med,2004

2. Determinants of virological response to antiretroviral therapy: implications for long-term strategies;Deeks;Clin Infect Dis,2000

3. Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients;Turner;J Infect Dis,2002

4. Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence;Press;J Acquir Immune Defic Syndr,2002

5. The pharmacogenetics of antiretroviral therapy: a review of studies to date;Quirk;Clin Infect Dis,2004

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Secuenciación de la CYP3A4, evaluación de la actividad de la colinesterasa y geolocalización de trabajadores expuestos en comunidad agraria de la Colonia Tovar, Venezuela;Revista Mexicana de Patología Clínica y Medicina de Laboratorio;2020

2. Efavirenz loaded nanostructured lipid carrier engineered for brain targeting through intranasal route: In-vivo pharmacokinetic and toxicity study;Biomedicine & Pharmacotherapy;2017-10

3. Poly(ɛ-caprolactone), Eudragit® RS 100 and poly(ɛ-caprolactone)/Eudragit® RS 100 blend submicron particles for the sustained release of the antiretroviral efavirenz;Colloids and Surfaces B: Biointerfaces;2013-02

4. High-Technology Therapy Using Biomolecules or Synthetic Compounds for HIV Inhibition;Nanomedicine for Drug Delivery and Therapeutics;2013-01-30

5. Drug delivery systems in HIV pharmacotherapy: What has been done and the challenges standing ahead;Journal of Controlled Release;2009-08